PT-141 (10mg)

Central Melanocortin Receptor Agonist (Bremelanotide)

PT-141 (10mg) will be supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.

PT-141, also known as Bremelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It is studied for CNS-mediated mechanisms — acting on melanocortin receptors (MC3-R and MC4-R) in the brain rather than through peripheral vascular pathways. This distinguishes PT-141 from PDE5 inhibitors (sildenafil, tadalafil), which act on peripheral vasodilation.

A modified pharmaceutical form (bremelanotide) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.

Key Research Areas

• Sexual Arousal Pathways — Studied for central melanocortin receptor activation in both male and female research models
• Hypoactive Sexual Desire — Studied in models where the underlying mechanism is neurological rather than vascular
• Cross-Sex Research — Studied across male and female models, distinguishing it from PDE5 inhibitors primarily indicated for male erectile dysfunction
• Melanocortin System — Research tool for studying melanocortin pathways in mood, motivation, and reward beyond sexual function

Supplied as lyophilized powder at 99.896% purity as reported on the CoA, verified by HPLC and mass spectrometry. 10mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.